ZVRA - Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. , a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
As of May 15, 2026: spot at $11.07, ATM IV 61.1%, max pain $10.00, net GEX $932.0K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $657.4M
- P/E Ratio
- 5.23
- Beta
- 0.88
- 52-Week Range
- 7.16-13.16
- CEO
- Neil F. McFarlane
- Employees
- 59
- IPO Date
- Apr 16, 2015
- Exchange
- NASDAQ
What ZVRA Looks Like to Options Traders Today
IV rank of 14.9% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($932.0K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.256) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The ZVRA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ZVRA overview questions
- What is ZVRA?
- ZVRA is the ticker symbol for Zevra Therapeutics, Inc., a listed security. Zevra Therapeutics, Inc. , a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. Listed on NASDAQ. ZVRA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ZVRA options snapshot look like today?
- As of May 15, 2026, the ZVRA options snapshot shows spot at $11.07, ATM IV 61.1%, IV rank 14.9%, max pain $10.00, net GEX $932.0K, expected move 17.52%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ZVRA's key statistics?
- Zevra Therapeutics, Inc. (ZVRA) carries a market capitalization of $657.4M, trailing P/E ratio of 5.23, beta of 0.88 relative to the broader market, 52-week range of 7.16-13.16. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ZVRA belong to?
- Zevra Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ZVRA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ZVRA data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).